Neos Therapeutics, Inc. (NEOS) financial statements (2021 and earlier)
Company profile
| Business Address |
2940 N. HIGHWAY 360 GRAND PRAIRIE, TX 75050 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 25 | 25 | 30 | 40 | 46 | 17 | 28 | ||
| Cash and cash equivalents | 17 | 23 | 26 | 33 | 46 | 17 | 18 | ||
| Short-term investments | 8 | 2 | 4 | 7 | 10 | ||||
| Receivables | 27 | 29 | 20 | 23 | 28 | 20 | 18 | ||
| Inventory, net of allowances, customer advances and progress billings | 11 | 12 | 12 | 11 | 10 | 12 | 13 | ||
| Inventory | 11 | 12 | 12 | 11 | 10 | 12 | 13 | ||
| Other current assets | 2 | 2 | 3 | 4 | 1 | 1 | |||
| Other undisclosed current assets | 4 | ||||||||
| Total current assets: | 67 | 68 | 65 | 77 | 89 | 50 | 60 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3 | 3 | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 7 | 8 | 8 | 8 | 8 | 8 | 8 | ||
| Intangible assets, net (including goodwill) | 13 | 13 | 14 | 14 | 15 | 15 | 16 | ||
| Intangible assets, net (excluding goodwill) | 13 | 13 | 14 | 14 | 15 | 15 | 16 | ||
| Other noncurrent assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed noncurrent assets | 3 | 3 | |||||||
| Total noncurrent assets: | 24 | 24 | 25 | 25 | 23 | 23 | 24 | ||
| TOTAL ASSETS: | 91 | 92 | 89 | 102 | 111 | 73 | 84 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 47 | 44 | 40 | 43 | 49 | 37 | 40 | ||
| Accounts payable | 7 | 7 | 7 | 9 | 13 | 8 | 6 | ||
| Accrued liabilities | 40 | 38 | 34 | 34 | 36 | 30 | 34 | ||
| Debt | 2 | 2 | 9 | 9 | 16 | 16 | |||
| Other undisclosed current liabilities | 15 | 15 | 17 | 1 | |||||
| Total current liabilities: | 63 | 61 | 57 | 52 | 57 | 53 | 56 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation, including: | 4 | 4 | 43 | 43 | 44 | 44 | |||
| Finance lease, liability | 0 | 0 | ✕ | ✕ | ✕ | ||||
| Operating lease, liability | 3 | 3 | ✕ | ✕ | ✕ | ||||
| Other undisclosed long-term debt and lease obligation | 43 | 43 | 44 | 44 | |||||
| Liabilities, other than long-term debt | 1 | 1 | 2 | 2 | 3 | 3 | 3 | ||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 1 | ||
| Deferred rent credit | 1 | 1 | |||||||
| Other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Derivative instruments and hedges, liabilities | 1 | 1 | 1 | 2 | 2 | 1 | 1 | ||
| Other undisclosed noncurrent liabilities | 29 | 28 | 32 | 4 | |||||
| Total noncurrent liabilities: | 34 | 34 | 34 | 49 | 46 | 46 | 46 | ||
| Total liabilities: | 97 | 95 | 91 | 101 | 104 | 100 | 103 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (6) | (3) | (2) | 1 | 8 | (27) | (19) | ||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Treasury stock, value | (0) | (0) | (0) | (0) | (0) | (0) | (0) | ||
| Additional paid in capital | 328 | 328 | 327 | 326 | 325 | 281 | 277 | ||
| Accumulated other comprehensive income (loss) | 0 | 0 | (0) | 0 | |||||
| Accumulated deficit | (334) | (330) | (328) | (325) | (317) | (308) | (295) | ||
| Total stockholders' equity: | (6) | (3) | (2) | 1 | 8 | (27) | (19) | ||
| TOTAL LIABILITIES AND EQUITY: | 91 | 92 | 89 | 102 | 111 | 73 | 84 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 17 | 18 | 16 | 15 | 15 | 13 | 11 | |
| Cost of revenue (Cost of Goods and Services Sold) | (7) | (6) | (5) | (6) | (8) | (7) | (7) | |
| Gross profit: | 10 | 11 | 11 | 8 | 8 | 6 | 4 | |
| Operating expenses | (11) | (12) | (13) | (14) | (15) | (16) | (18) | |
| Operating loss: | (2) | (0) | (2) | (6) | (7) | (10) | (13) | |
| Nonoperating income (Other Nonoperating income) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Interest and debt expense | (2) | (2) | (2) | (2) | (2) | (2) | (2) | |
| Loss from continuing operations before income taxes: | (3) | (2) | (4) | (8) | (9) | (13) | (15) | |
| Other undisclosed loss from continuing operations | (0) | |||||||
| Net loss available to common stockholders, diluted: | (3) | (2) | (4) | (8) | (9) | (13) | (15) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (3) | (2) | (4) | (8) | (9) | (13) | (15) | |
| Comprehensive loss: | (3) | (2) | (4) | (8) | (9) | (13) | (15) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 0 | (0) | 0 | (0) | (0) | 0 | ||
| Comprehensive loss, net of tax, attributable to parent: | (3) | (2) | (4) | (8) | (9) | (13) | (15) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.